Browse All

Current Filters

CLEAR FILTER x

TITLE

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN

Author:Carter, Lawrence   Borroni, Barbara   Mummery, Catherine   Le Ber, Isabelle   Boeve, Bradley   Boxer, Adam   Smithey, Megan   Chow, Tiffany   Huang, Julie   Guizzetti, Leonardo   Salvadore, Giacomo   Romano, Gary   

Session Name:P8: Aging, Dementia, and Behavioral Neurology: Non-AD Treatments  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:P8.005  

Author Institution:Alector, South San Francisco, CA